761440-55-5Relevant academic research and scientific papers
Synthesis and Preliminary Evaluation of [11C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease
Chen, Zhen,Shao, Tuo,Gao, Wei,Fu, Hualong,Collier, Thomas Lee,Rong, Jian,Deng, Xiaoyun,Yu, Qingzhen,Zhang, Xiaofei,Davenport, April T.,Daunais, James B.,Wey, Hsiao-Ying,Shao, Yihan,Josephson, Lee,Qiu, Wen-Wei,Liang, Steven
, p. 1580 - 1585 (2019/08/30)
Leucine-rich repeat kinase 2 (LRRK2) is a large protein involved in the pathogenesis of Parkinson's disease (PD). It has been demonstrated that PD is mainly conferred by LRRK2 mutations that bring about increased kinase activity. As a consequence, selecti
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors
Ding, Xiao,Stasi, Luigi Piero,Ho, Ming-Hsun,Zhao, Baowei,Wang, Hailong,Long, Kai,Xu, Qiongfeng,Sang, Yingxia,Sun, Changhui,Hu, Huan,Yu, Haihua,Wan, Zehong,Wang, Lizhen,Edge, Colin,Liu, Qian,Li, Yi,Dong, Kelly,Guan, Xiaoming,Tattersall, F. David,Reith, Alastair D.,Ren, Feng
supporting information, p. 1615 - 1620 (2018/03/29)
Inhibition of LRRK2 kinase activity with small molecules has emerged as a potential novel therapeutic treatment for Parkinson's disease. Herein we disclose the discovery of a 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine series as potent LRRK2 inhibitors id
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00679; 00680, (2018/04/27)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
Synthesis of [11C]HG-10-102-01 as a new potential PET agent for imaging of LRRK2 enzyme in Parkinson's disease
Wang, Min,Gao, Mingzhang,Xu, Zhidong,Zheng, Qi-Huang
, p. 1351 - 1355 (2017/03/08)
The reference standard (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-methoxyphenyl)(morpholino)methanone (HG-10-102-01) and its precursor (4-((5-chloro-4-(methylamino)pyrimidin-2-yl)amino)-3-hydroxyphenyl)(morpholino)methanone (desmethyl-HG-10-102-
Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor
Hatcher, John M.,Zhang, Jinwei,Choi, Hwan Geun,Ito, Genta,Alessi, Dario R.,Gray, Nathanael S.
, p. 584 - 589 (2015/05/27)
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrrolopyrimidine, JH-II-127 (18
Brain penetrant LRRK2 inhibitor
Choi, Hwan Geun,Zhang, Jinwei,Deng, Xianming,Hatcher, John M.,Patricelli, Matthew P.,Zhao, Zheng,Alessi, Dario R.,Gray, Nathanael S.
supporting information, p. 658 - 662 (2013/01/14)
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here, we report that a 2-anilino-4-methylamino-5- chloropyrimidine, HG-10-102-01
2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS
-
Page 118; 127, (2010/02/08)
Novel pyrimidine derivatives of formula (I), to processes for their production, their use as pharmaceuticals in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.
